Authors
Latest:
Managing post-prostatectomy incontinence in patients with comorbidities"Most of these comorbidities, while they do affect the bladder, don't seem to affect the surgeries for stress urinary incontinence," says Jaspreet S. Sandhu, MD.
Latest:
UT Money Matters: Roth IRA conversionsExpert insight on pros, cons and optimal strategies when considering converting a traditional IRA to a Roth IRA.
Latest:
Investigators evaluate tamsulosin use in pediatric patients"We recognize that an 11% increase in success may not seem that clinically significant, but I think every little bit helps," says Kate H. Kraft, MD, MHPE, FACS, FAAP.
Latest:
Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape“I think we now have really robust data showing that earlier treatment intensification with combination regimens does lead to improved survival for patients with metastatic hormone-sensitive prostate cancer," says Dr Louise Kostos.
Latest:
How to implement an ERAS pathway in your urology practiceProgram encompasses patient counseling, anesthetic planning, and early mobilization.
Latest:
Kari Bailey, MD, on the evolving priorities of women in urology"Things that were typically used to recruit younger physicians need to change because those aren't their priorities anymore," says Kari Bailey, MD.
Latest:
How to approach immune checkpoint inhibitor therapy in prostate cancerNext-generation sequencing identifies subtypes that may benefit from immune checkpoint inhibitors.
Latest:
Advanced bladder cancer patients could keep their bladder under new treatment regime, clinical trial showsAn approach combining chemotherapy and immunotherapy could help preserve quality of life.
Latest:
CVAC2 shows safety, efficacy for stone clearance in real-world study“The data presented at EAU25 add to the growing body of evidence supporting the CVAC System as the emerging standard of care in kidney stone removal,” says Brett Johnson, MD.
Latest:
Emerging Therapies for Metastatic Castration-Resistant Prostate CancerRobert Dreicer, MD, describes the future of metastatic castration-resistant prostate cancer.
Latest:
Future Perspectives in the Treatment of Patients With Urinary StonesDrs Bechis and Semins discuss future developments in urinary stone management, emphasizing the potential for improved vacuum aspiration devices, combined intravenous and PCNL surgeries, and the hope for medications to dissolve stones.
Latest:
Jindan Yu, MD, highlights ongoing prostate cancer research projects"We are trying to develop epigenetic biomarkers that can predict patients that are starting to progress to neuroendocrine prostate cancer," says Jindan Yu, MD, PhD.
Latest:
The benefits of working with a consultant when starting a private urology practice"Just having someone with another set of eyes I think is always helpful and gives you a lot of inspiration as well as a lot of encouragement on exactly what you need to do next," says Gia Ching.
Latest:
Demystifying Vector-Based Intravesical Gene Therapy for NMIBC: A New FrontierNeal Shore, MD, FACS, is a U.S. Chief Medical Officer at GenesisCare USA and Medical Director of the Carolina Urologic Research Center. He also was an investigator on the Phase 2 and 3 studies in the clinical trial program for nadofaragene firadenovec-vncg.
Latest:
Optimizing Multidisciplinary Care for BCG-Naive, High-Risk NMIBCPanelists discuss the characteristics of an ideal multidisciplinary team for managing BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC), emphasizing the need for oncologists and urologists to collaboratively prepare for successful patient outcomes across different markets, while also identifying necessary educational resources and highlighting adverse events that require attention in preparation for product launches.
Latest:
Pooja Ghatalia, MD, on interim findings from RETAIN-2 trial in MIBC"We see that among the patients who went on to receiving cystectomy, 84% are metastases free," says Pooja Ghatalia, MD.
Latest:
The role of surgery continues to evolve in seminoma"RPLND is an attractive option for those who prefer to avoid chemotherapy," write Jiping Zeng, MD; Timothy A. Masterson, MD; and Clint Cary, MD, MPH, MBA.
Latest:
PARP inhibitors: Treating mCRPC from a genetic basisTreatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Latest:
Diversity in Urology: Progress made, but there is more work to be doneKelvin Moses, MD, PhD, interviews Tracy M. Downs, MD, about progress and remaining challenges regarding diversity, equity, and inclusion in the field of urology.
Latest:
Sarah Psutka, MD, on phase 3 trial of padeliporfin VTP therapy in UTUC“This is another therapeutic that adds to UroGen [profile] as a potential treatment that could be used to preserve kidneys while treating low grade upper tract urothelial carcinoma going forward,” says Sarah P. Psutka, MD, MSc.
Latest:
The evolving role of microRNAs in testicular cancer management"This brief review captures the evolving role of miRNAs, focusing on their clinical relevance and implications as well as future directions for more effective targeted therapeutic interventions," write the authors.
Latest:
Kara Cossis, PA-C, MPH, on the role of APPs in genetic testingAPPs can help in introducing genetic testing and in the interpretation of results, according to Kara Cossis, PA-C, MPH.
Latest:
Investigators characterize vibegron prescribing patterns for OAB"We found that the location that prescribers were registered in, as well as their fellowship training, was significantly associated with higher vibegron prescription rates,” says Grace Khaner.
Latest:
What steps can physicians take to overcome barriers to health equity?“Things we have control over are ourselves, our care team, and to some extent, our care model,” said Sarah Candler, MD.
Latest:
Expert shares anticipated research directions for PSMA-PET in prostate cancer"I would basically look at these 3 things as the major things to be coming up," says Jitesh Dhingra, MD, FRCEM.
Latest:
177Lu-PSMA-617 prolongs rPFS in taxane-naïve mCRPC, benefit greater with prior abiraterone vs enzalutamideLutetium Lu 177 vipivotide tetraxetan improved rPFS vs switching to abiraterone acetate or enzalutamide in patients with taxane-naïve mCRPC who had progressed on prior abiraterone or enzalutamide. Outcomes were better, however, in patients who initially received abiraterone.
Latest:
Brendan Frainey, MD, on microbiome composition in patients with spina bifida"The notion that the urine is sterile should be hopefully abolished by now, especially in this group where we know that these individuals do have a lot of bacteria growing in their bladders," says Brendan T. Frainey, MD.
Latest:
Kara Watts, MD, outlines SUO 2024 session on salvage focal ablation"I think the highlights are the functional outcomes after a salvage focal ablation are favorable, definitely, compared to salvage radical prostatectomy, but the studies are quite limited in terms of real salvage focal ablation," says Kara L. Watts, MD.
Latest:
The role of surgery continues to evolve in seminoma"RPLND is an attractive option for those who prefer to avoid chemotherapy," write Jiping Zeng, MD; Timothy A. Masterson, MD; and Clint Cary, MD, MPH, MBA.
Latest:
Potential Impact of PET/CT Imaging on Improving Patient CareNeal Shore, MD, FACS, and Brian Shuch, MD, provide closing thoughts on the potential of PET/CT imaging to improve patient care in kidney cancer.
